Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cipla Takes To Future Therapies With Stempeutics Pact; Says Preparing For The Big Changes In Research

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Future sciences like monoclonal antibodies or stem cell therapies are not just attracting the fancy of multinational companies scrambling to expand their pipelines; even generic drug makers like India's Cipla are getting drawn into start-up companies and demonstrating an ability to bring to market products that can potentially revolutionalize treatment regimens

You may also be interested in...



Cipla Backs Chase For Alzheimer’s Drug Research

The top-tier Indian generic company is moving fast into unexpected research territories. In the latest announcement, Cipla said it will partly fund Chase’s Alzheimer’s programs and keep looking for more such opportunities.

Cipla Backs Chase For Alzheimer’s Drug Research

The top-tier Indian generic company is moving fast into unexpected research territories. In the latest announcement, Cipla said it will partly fund Chase’s Alzheimer’s programs and keep looking for more such opportunities.

After Death Of Cipla Former Joint Managing Director Amar Lulla, Will Vision Of Veteran Continue?

MUMBAI - After jointly serving at the helm of Cipla for more than three decades, Joint Managing Director Amar Lulla died April 22 after a prolonged and debilitating battle with cancer. To the world, Cipla Chairman Yusuf Hamied was the face of the company - fighting global pharmaceutical companies to bring down prices of anti-HIV and anti-cancer medications - but to those within the organization, Lulla remained the single driving force, handling the complexities of the generic drugs market in India and working steadily to keep Cipla competitive

Related Content

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel